3 sources checked · 2 source groups included · 2h ago
Still Watching
STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Remarkable new test results by drugmaker Eli Lilly reveal that their latest weight loss drug, retatrutide, may be even more effective than the three popular GLP-1s currently available. The new drug is designed to mimic three hormones responsible for hunger regulation and fat burning. NBC’s medical...
2 Left1 Center0 Right
Still watching.Optics is waiting for a cleaner match before calling the split.
STILL WATCHING
As of May 21, 2026 at 12:04 PM, this is how Optics News reads the wording differences in this story.
What happenedA next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
The headline splitOne side frames it as "New Weight Loss Drug Retatrutide Delivers Stunning Results". The other frames it as "STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial".
Can I trust it?Yes. 3 sources checked across 2 bias buckets.
WHAT EACH SIDE EMPHASIZED
Left / center-leftNew Weight Loss Drug Retatrutide Delivers Stunning Results
NBC News · Center-left · News report
CenterSTAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
STAT News · Center · News report
Right / center-rightNo matching source in this bucket yet.
New Weight Loss Drug Retatrutide Delivers Stunning Results
retatrutidedeliversstunningresults
Remarkable new test results by drugmaker Eli Lilly reveal that their latest weight loss drug, retatrutide, may be even more effective than the three popular GLP-1s currently available. The...
STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
statlillystriple-gleadsbariatric-surgery
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
